Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742035 | 0.84 | MEN1 (0.47) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL8668995 | 0.81 | ALDH1A1 (0.46) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL11530868 | 0.78 | PKM (0.41) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL18839851 | 0.78 | PKM (0.47) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL7510796 | 0.73 | PKM (0.43) | PKMATMHSD17B10 | |
| SCHEMBL7509741 | 0.73 | PKM (0.43) | PKMATMHSD17B10 | |
| SCHEMBL24018479 | 0.72 | MEN1 (0.44) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL6775540 | 0.72 | RECQL (0.44) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL17686526 | 0.72 | ALDH1A1 (0.47) | PKMATMHSD17B10MEN1KMT2A | |
| SCHEMBL24666635 | 0.68 | MEN1 (0.41) | PKMATMHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | claimed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | claimed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | claimed |
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |